June 12, 2020 – The U.S. FDA has approved UpliznaTM (inebilizumab-cdon), manufactured by Viela Bio, to
treat neuromyelitis optica spectrum disorder (NMOSD) in adults who test positive
June 12, 2020 – The U.S. FDA has approved Tivicay® PD (dolutegravir) tablets for oral suspension,
manufactured by ViiV Healthcare, for use in combination with other
May 15, 2020 – The U.S. FDA has approved a new indication for Pomalyst® (pomalidomide), manufactured
by Bristol Myers Squibb. It is indicated to treat AIDS-related Kaposi sarcoma
May 15, 2020 – The U.S. FDA has approved QinlockTM (ripretinib), manufactured by Deciphera
Pharmaceuticals, to treat adult patients who have advanced gastrointestinal
May 15, 2020 – The U.S. FDA has approved a new indication for Rubraca® (rucaparib), manufactured by
Clovis Oncology. Rubraca is now indicated to treat adult patients who have
May 11, 2020 – The U.S. FDA has approved a new indication for Lynparza® (olaparib), manufactured by
AstraZeneca. Lynparza is now indicated for use in combination with bevacizumab
May 08, 2020 – By now, you may have heard of something called convalescent plasma therapy in the news. It’s a therapy that’s been in use for about a century.